Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Original paper

TROP-2 expression in triple-negative and human epidermal growth facto r recepto r 2 enriched breast cancers and its relationship with clinicopathologic parameters

Hale Kivrak
1
,
Duygu Turkbey Simsek
1
,
Egemen Akincioglu
1
,
Ilke Evrim Seçinti
2
,
Gül Sema Yildiran Keskin
3
,
Ismail Erturk
3
,
Murat Demiriz
1

  1. Department of Pathology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey
  2. Department of Pathology, Silifke State Hospital, Silifke/Mersin, Turkey
  3. Department of Medical Oncology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey
Pol J Pathol 2025; 76 (3)
DOI: https://doi.org/10.5114/pjp.2025.156555
Online publish date: 2025/11/28
Article file
- TROP-2 expression.pdf  [4.01 MB]
Get citation
 
PlumX metrics:
 
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.
2. Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet 2019; 394: 793-804.
3. Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 2024; 21: 203-223.
4. Zaman S, Jadid H, Denson AC, Gray JE. Targeting TROP-2 in solid tumors: future prospects. Onco Targets Ther 2019; 12: 1781-90.
5. Yao L, Chen J, Ma W. Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. Front Oncol 2023; 13: 1292211.
6. Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, et al. Trop-2 is a determinant of breast cancer survival. PLoS One 2014; 9: e96993.
7. Izci H, Punie K, Waumans L, Laenen A, Wildiers H, Verdoodt F, et al. Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer. Sci Rep 2022; 12: 22498.
8. Chartier S, Brochard C, Martinat C, Coussy F, Feron JG, Kirova Y, et al. TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas. Histopathology 2023; 82: 664-671.
9. Jeon Y, Jo U, Hong J, Gong G, Lee HJ, et al. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer 2022; 22: 1014.
10. Sakach E, Sacks R, Kalinsky K. Trop-2 as a therapeutic target in breast cancer. Cancers (Basel) 2022; 14.
11. Lokuhetty D, White V, Watanabe R, Cree I. WHO Classification of Breast Tumours. 5th ed. WHO, Geneva 2019.
12. Yang X, Hu Y, Shi H, Zhang C, Wang Z, Liu X, et al. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Eur Arch Otorhinolaryngol 2018; 275: 2127-21234.
13. Yeung V, Zaemes J, Yeh J, Giancarlo C, Ahn J, Reuss JE, et al. High levels of expression of Trop-2 in thymic epithelial tumors. Lung Cancer 2023; 184: 107324.
14. Van Bockstal MR, Depelsemaeker MC, Daoud L, Fontanges Q, Francois A, Guiot Y, et al. Evaluation of trophoblast cell surface antigen-2 (TROP2) protein expression in chemotherapy-resistant and metastatic breast carcinomas. Pathol Res Pract 2024; 264: 155724.
15. Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 2021; 32: 1148-1156.
16. Zeng P, Chen MB, Zhou LN, Tang M, Liu CY, Lu PH, et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep 2016; 6: 33658.
17. Gion M, Garcia-Mosquera JJ, Perez-Garcia JM, Peg V, Ruiz-Borrego M, Stradella A, et al. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. Breast Cancer Res Treat 2024; 205: 589-598.
18. Lai J, Deng S, Cao J, Ren Y, Xu Z, Qi X, et al. Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy. Discov Oncol 2024; 15: 413.
19. Aslan M, Hsu EC, Garcia-Marques FJ, Bermudez A, Liu S,  Shen M, et al. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer 2021; 7: 141.
20. Mertens RB, Makhoul EP, Li X, Dadmanesh F. Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: an immunohistochemical study of 94 therapy-naive primary breast tumors. Ann Diagn Pathol 2024; 68: 152226.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.